Tofacitinib versus standard of care treatment in patients with COVID-19: a multicenter non-randomized controlled study
Sergey Moiseev,1 Nikolay Bulanov,1Anastasiia Zykova,2 Michail Brovko,1Pavel Novikov,1 Larisa Akulkina,1Natalya Chichkova,3 Natalya Trushenko,4 Maria Lukina,5 Yuriy Sorokin,1 Ekaterina Tao,1 Ekaterina Filatova,1 Aram Kitbalyan,1,2 Pavel Potapov,1,2 Lubov Ermolova,1 Olga Suvorova,4 Augusto Vaglio,6 Andreas Kronbichler,7 Sergey Avdeev,4 Victor Fomin3
1Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia,
2Department of Internal Medicine, Lomonosov Moscow State University, Moscow, Russia,
3Vinogradov Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia,
4Clinic of Pulmonology, Sechenov First Moscow State Medical University, Moscow, Russia,
5Department of Clinical Pharmacology and Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia
6Department of Biomedical Experimental and Clinical Sciences “Mario Serio”, University of Firenze, and Nephrology Unit, Meyer Children’s Hospital, Firenze, Italy,
7Department of Medicine, University of Cambridge, Cambridge, United Kingdom
Running title: Tofacitinib for COVID-19 pneumonia